



Stern Investor Relations is a leading investor relations (IR) firm specializing in providing IR consulting services to biotechnology, pharmaceutical and clean technology companies in the U.S. and around the world. Since our inception in 1998, we have worked with over 200 companies in all stages of development, including bellwethers in the industry, small- and mid-cap companies, recent IPOs and private companies.

- **Specialization in healthcare and clean tech investor relations**
- **Strong relationships with the investment community**
- **Focus on best industry practices**

Clients

- Acceleron Pharma
- Acorda Therapeutics
- Agios Pharmaceuticals
- Alkermes
- Allos Therapeutics
- Alnylam Pharmaceuticals
- AMAG Pharmaceuticals
- Avila Therapeutics
- BioSpecifics Technologies
- Curis
- Endocyte
- Gevo
- ImmunoGen
- Infinity Pharmaceuticals
- Ironwood Pharmaceuticals
- Mascoma
- Mesoblast
- Millennium: The Takeda Oncology Company
- Mission NewEnergy
- Momenta Pharmaceuticals
- NeuroMetrix
- Rexahn Pharmaceuticals
- SciClone Pharmaceuticals
- SkinMedica
- Tengion
- Verenum

Approach

Our ultimate goal is to help each client realize an external valuation that best reflects the company's true value through productive interactions with the investment community.

We believe that a successful investor relations program depends on a multifaceted approach, including effective strategy and tactical execution. Thoughtful strategic advice, commitment to execution and a careful attention to detail are central to our approach.

We aim to provide cost-effective investor relations counsel and support and to maximize the impact of our clients' time and effort.



Services

Working closely with each client, we develop and execute a customized strategic investor relations program designed to manage communications effectively with the investment community. We provide each client with senior level attention, strategic counsel and critical, disciplined tactical support.

Stern IR offers a broad range of investor relations services that includes working with senior management to achieve key investor relations goals, such as effective positioning, enhancing visibility, improving institutional ownership and sell-side coverage, preparing for financings and IPOs, developing good guidance practices and managing communications around M&A, binary events and other strategic issues.



Contact

Stern Investor Relations, Inc.
New York, New York
212.362.1200
info@sternir.com



Strategic & Tactical IR

- Each relationship begins with an analysis of the client's investment considerations, including perceived strengths and challenges and upcoming news items and milestones.
- We then develop documents to help guide our communications and outreach strategies, including corporate messaging, a client-catered yearly calendar, an outreach plan and a sophisticated analyst and investor targeting analysis program.
- We provide full tactical and event planning support, assisting with various IR events, including roadshows (sell-side, bank-sponsored, non-deal and investor conferences), Analyst and Investor days and events, earnings and news announcements and events at medical meetings.
- We assist with the development of news releases, fact sheets, FAQs, annual reports and other IR-related documents.

Team

Our team of experienced, analytical, IR professionals offers a proven track record of delivering results. Years of experience and superior client service allow us to provide sophisticated and critical direction, unique insights and a total perspective to meet clients' needs.